EA200500610A1 - Композиция для лечения инфекции, вызываемой вирусами семейств flaviviridae - Google Patents
Композиция для лечения инфекции, вызываемой вирусами семейств flaviviridaeInfo
- Publication number
- EA200500610A1 EA200500610A1 EA200500610A EA200500610A EA200500610A1 EA 200500610 A1 EA200500610 A1 EA 200500610A1 EA 200500610 A EA200500610 A EA 200500610A EA 200500610 A EA200500610 A EA 200500610A EA 200500610 A1 EA200500610 A1 EA 200500610A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- composition
- viruses
- treatment
- infection caused
- alkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Abstract
В заявке описаны композиции, применение, изделие и способ лечения млекопитающего, зараженного вирусом семейства Flaviviridae, заключающийся в том, что зараженному млекопитающему вводят соединение формулы (I)в которой A выбирают из C-C-алкила и C-C-циклоалкила; B выбирают из фенила или тиазолила, каждый из которых необязательно замещен группой, выбранной из NH(R) и NH(CO)R, где Rобозначает C-C-алкил; и R обозначает OH или сульфонамидное производное, или его фармацевтически приемлемую соль.Международная заявка была опубликована вместе с отчетом о международном поиске.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42190002P | 2002-10-29 | 2002-10-29 | |
US44276903P | 2003-01-27 | 2003-01-27 | |
PCT/CA2003/001634 WO2004039833A1 (en) | 2002-10-29 | 2003-10-24 | Composition for the treatment of infection by flaviviridae viruses |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200500610A1 true EA200500610A1 (ru) | 2005-10-27 |
Family
ID=32233460
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200500610A EA200500610A1 (ru) | 2002-10-29 | 2003-10-24 | Композиция для лечения инфекции, вызываемой вирусами семейств flaviviridae |
Country Status (13)
Country | Link |
---|---|
US (1) | US20050159345A1 (ru) |
EP (1) | EP1558633A1 (ru) |
JP (1) | JP2006517196A (ru) |
KR (1) | KR20050061592A (ru) |
AU (1) | AU2003275852A1 (ru) |
BR (1) | BR0315781A (ru) |
CA (1) | CA2498642A1 (ru) |
EA (1) | EA200500610A1 (ru) |
EC (1) | ECSP055815A (ru) |
MX (1) | MXPA05004604A (ru) |
NO (1) | NO20052580L (ru) |
PL (1) | PL376409A1 (ru) |
WO (1) | WO2004039833A1 (ru) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2268391A1 (en) | 1996-10-18 | 1998-04-30 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
US6867185B2 (en) * | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
US7176208B2 (en) * | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
ATE500264T1 (de) * | 2003-09-22 | 2011-03-15 | Boehringer Ingelheim Int | Makrozyklische peptide mit wirkung gegen das hepatitis-c-virus |
CA2549851C (en) | 2004-01-21 | 2012-09-11 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis c virus |
SI1713823T1 (sl) | 2004-01-30 | 2010-04-30 | Medivir Ab | Inhibitorji HCV NS-3 serin proteaze |
PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
US8076365B2 (en) | 2005-08-12 | 2011-12-13 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
US7816348B2 (en) | 2006-02-03 | 2010-10-19 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
MX2009000882A (es) | 2006-08-17 | 2009-02-04 | Boehringer Ingelheim Int | Inhibidores de la polimerasa virica. |
US20080182895A1 (en) * | 2006-08-25 | 2008-07-31 | Howe Anita Y M | Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto |
JP2010535156A (ja) | 2007-08-03 | 2010-11-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ウイルスポリメラーゼ阻害剤 |
CN101977621A (zh) | 2007-12-05 | 2011-02-16 | 益安药业 | 氟化三肽hcv丝氨酸蛋白酶抑制剂 |
KR20100098534A (ko) | 2007-12-19 | 2010-09-07 | 베링거 인겔하임 인터내셔날 게엠베하 | 바이러스 폴리머라제 억제제 |
EP2334680A2 (en) * | 2008-08-20 | 2011-06-22 | Sequoia Pharmaceuticals, Inc. | Hcv protease inhibitors |
UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
KR20110116136A (ko) | 2009-01-07 | 2011-10-25 | 싸이넥시스, 인크. | Hcv 및 hiv 감염의 치료에 사용하기 위한 사이클로스포린 유도체 |
EP2429568B1 (en) | 2009-05-13 | 2016-08-17 | Enanta Pharmaceuticals, Inc. | Macrocyclic compounds as hepatitis c virus inhibitors |
US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
WO2011063501A1 (en) * | 2009-11-24 | 2011-06-03 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor compounds |
WO2011063502A1 (en) * | 2009-11-24 | 2011-06-03 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor compounds |
JP5857053B2 (ja) | 2010-09-21 | 2016-02-10 | エナンタ ファーマシューティカルズ インコーポレイテッド | 大環式プロリン由来hcvセリンプロテアーゼ阻害剤 |
EP2658858A4 (en) | 2010-12-30 | 2014-06-25 | Enanta Pharm Inc | MACROCYCLIC INHIBITORS OF HEPATITIS C SERINE PROTEASE PHENANTHRIDINE |
MX2013007677A (es) | 2010-12-30 | 2013-07-30 | Abbvie Inc | Inhibidores macrociclicos de serina proteasa de hepatitis. |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
PT2861604T (pt) * | 2012-06-08 | 2017-05-05 | Gilead Sciences Inc | Inibidores macrocíclicos de vírus flaviridae |
WO2013185090A1 (en) | 2012-06-08 | 2013-12-12 | Gilead Sciences, Inc. | Macrocyclic inhibitors of flaviviridae viruses |
AR091279A1 (es) | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
KR101446049B1 (ko) * | 2013-01-14 | 2014-10-01 | 전남대학교산학협력단 | 뎅기 바이러스 관련 질환의 치료 또는 예방용 조성물 |
WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
JP7497790B2 (ja) * | 2019-12-27 | 2024-06-11 | 国立大学法人北海道大学 | 豚コレラの治療及び/又は予防剤 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6608027B1 (en) * | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
UA74546C2 (en) * | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
US6867185B2 (en) * | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
CA2369711A1 (en) * | 2002-01-30 | 2003-07-30 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
US6828301B2 (en) * | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
-
2003
- 2003-10-16 US US10/687,204 patent/US20050159345A1/en not_active Abandoned
- 2003-10-24 EA EA200500610A patent/EA200500610A1/ru unknown
- 2003-10-24 PL PL03376409A patent/PL376409A1/xx not_active Application Discontinuation
- 2003-10-24 EP EP03809665A patent/EP1558633A1/en not_active Withdrawn
- 2003-10-24 WO PCT/CA2003/001634 patent/WO2004039833A1/en not_active Application Discontinuation
- 2003-10-24 CA CA002498642A patent/CA2498642A1/en not_active Abandoned
- 2003-10-24 AU AU2003275852A patent/AU2003275852A1/en not_active Abandoned
- 2003-10-24 BR BR0315781-4A patent/BR0315781A/pt not_active Application Discontinuation
- 2003-10-24 MX MXPA05004604A patent/MXPA05004604A/es not_active Application Discontinuation
- 2003-10-24 KR KR1020057007589A patent/KR20050061592A/ko not_active Application Discontinuation
- 2003-10-24 JP JP2005501790A patent/JP2006517196A/ja active Pending
-
2005
- 2005-05-24 EC EC2005005815A patent/ECSP055815A/es unknown
- 2005-05-27 NO NO20052580A patent/NO20052580L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2003275852A1 (en) | 2004-05-25 |
US20050159345A1 (en) | 2005-07-21 |
JP2006517196A (ja) | 2006-07-20 |
BR0315781A (pt) | 2005-09-13 |
MXPA05004604A (es) | 2005-07-13 |
WO2004039833A1 (en) | 2004-05-13 |
ECSP055815A (es) | 2005-08-11 |
KR20050061592A (ko) | 2005-06-22 |
NO20052580L (no) | 2005-07-20 |
NO20052580D0 (no) | 2005-05-27 |
EP1558633A1 (en) | 2005-08-03 |
PL376409A1 (en) | 2005-12-27 |
CA2498642A1 (en) | 2004-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200500610A1 (ru) | Композиция для лечения инфекции, вызываемой вирусами семейств flaviviridae | |
EA200400022A1 (ru) | Соединения и способы лечения или предупреждения инфекций flavivirus | |
EA200500723A1 (ru) | Соединения бензофурана, композиции и способы лечения и профилактики инфекций, вызванных вирусом гепатита c, и связанных с ним заболеваний | |
EA200800932A1 (ru) | Модифицированные 4`-нуклеозиды в качестве противовирусных агентов | |
NO20075723L (no) | Tiazolforbindelser og fremgangsmater for anvendelse | |
ATE447573T1 (de) | Chinoxalinyl-makrocyclische hepatitis c serin protease-hemmer | |
EA200702493A1 (ru) | Соединения и способы лечения или предотвращения флавивирусных инфекций | |
EA201101492A1 (ru) | Аналоги тиофена для лечения или предупреждения флавивирусных инфекций | |
DE60217114D1 (de) | Verbrückte bizyklische serinproteaseinhibitoren | |
EA200600892A1 (ru) | Новые хинолиновые производные | |
EA200500584A1 (ru) | Нуклеозидные производные для лечения инфекционных заболеваний, вызванных вирусом гепатита c | |
EA200300776A1 (ru) | Производные фенэтаноламина для лечения респираторных заболеваний | |
EA200501098A1 (ru) | Антибактериальные агенты | |
EA200900156A1 (ru) | Пиридазиновое соединение (варианты), способ его получения (варианты), способ лечения или профилактики инфекционного вирусного гепатита с с его помощью, композиция и лекарственное средство на его основе | |
EA200300318A1 (ru) | Пептидомиметические ингибиторы протеазы | |
EA200400886A1 (ru) | Макроциклические пептиды, обладающие активностью в отношении вируса гепатита c | |
EA200500814A1 (ru) | Производные пирролопиримидина | |
WO2005037860A3 (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
HK1101402A1 (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
EP2341065A3 (en) | Inhibitors of serine proteases, particularly HCV NS3-NS4a protease | |
NO20065736L (no) | Substituerte arylacyltioureaer og relaterte forbindelser; Inhibitorer av viral reproduksjon | |
NO20062146L (no) | Nukleosidforbindelser for behandling av virusinfeksjoner | |
ATE512976T1 (de) | Hemmer des hepatitis-c-virus | |
EA200901241A1 (ru) | Соединения для лечения гепатита с | |
WO2005035525A3 (en) | 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease |